Gershwin Blyden, M.D. – FDA Inspection, Sep 12, 2019

Record Details

This FDA Inspection record concerns Gershwin Blyden, M.D., with an inspection on September 12, 2019, issued by the Center for Drug Evaluation and Research, covering drugs.

Company: Gershwin Blyden, M.D.
Inspection Date: September 12, 2019
Product Type: Drugs
Office: Center for Drug Evaluation and Research
Person: Traci M. Armand (Company Rep)

View Company Profile

ID · b18a1885-fdf8-433d-bca9-e4e4a3836278

Inspection Facts

No Action Indicated (NAI)

No objectionable conditions or practices were found during the inspection.

Inspection number: 1101941
FDA center: Human Drugs
Project area: Bioresearch Monitoring
Outcome: Form 483 issued

FDA Citations

21 CFR 312.60FD-1572, protocol compliance
21 CFR 312.62(a)Accountability records
21 CFR 312.62(b)Case history records- inadequate or inadequate

Full citation text and observation details available on the Dashboard.

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Gershwin Blyden, M.D.

FDA Inspection

Gershwin Blyden, M.D.September 12, 2019